Back

The impact of dronedarone on patients with atrial fibrillation and diabetes - A sub-analysis of the ATHENA and EURIDIS/ADONIS trials

27 August 2021 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Atrial fibrillation e-posters Rhythm Control, Antiarrhythmic Drugs ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Doctor Yehuda Handelsman

The Metabolic Institute of America, Tarzana (United States of America)

160 More presentations in this session

Presentation thumbnail
The impact of abnormal conduction zone on outcomes after catheter ablation for atrial fibrillation
Associate Professor T. Mine (Nishinomiya, JP)
Abstract Slides
Presentation thumbnail
Thromboembolic risk of movable type left atrial appendage thrombi in patients with atrial fibrillation under widespread use of anticoagulants
Doctor M. Sugitani (Nishinomiya, JP)
Abstract Slides
Presentation thumbnail
Rate and rhythm control treatment in the elderly and very elderly patients with atrial fibrillation: an observational cohort study of 1,497 patients
Mr T. Klamer (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
One year outcome and analysis of peri-device leak of left atrial appendage occlusion devices
Doctor M. Mansour (Beirut, LB)
Abstract Slides
Presentation thumbnail
Risk prediction of atrial fibrillation and its complications in the community using high-sensitivity cardiac Troponin I: Results from the BiomarCaRE Consortium
Doctor C. Boerschel (Hamburg, DE)
Abstract Slides

Access the full session

Session thumbnail
Atrial fibrillation e-posters

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
1 September 2019
thumbnail
Congress Presentation
Clinical outcomes in patients with atrial fibrillation with or without concomitant diabetes after two years of edoxaban treatment: ETNA-AF-Europe registry
29 August 2022
thumbnail
Congress Presentation
Prevalence of atrial fibrillation and its associated factors among type 2 diabetics attending a tertiary hospital.
13 April 2023
thumbnail
Congress Presentation
LVA ablation following the PVI strategy showed better outcomes in diabetic patients with wide LVA compared to narrow LVA: A Sub-Analysis of the SUPPRESS-AF Trial
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources